Passionate about partnering, Amarin works collaboratively with strategic partners worldwide to maximise the value for patients. We have transitioned to a globally partned business model designed to maximize the value of our franchise asset, VASCEPA® / VAZKEPA® (icosapent ethyl), through strategic collaborations worldwide. Amarin prioritizes alliances with established global partners that bring deep market expertise, scale, and execution capability, while allowing Amarin to retain long‑term product value through supply, and milestone‑based economics. At Amarin, we believe in taking decisive steps to help patients globally, and that by joining with others we can reach our goals faster. Building alliances with complementary partners underlies our accomplishments to date and will help enhance our future successes.

Amarin has a network of experienced commercial partners for our product in focused geographies around the world where we do not have our own commercial teams. Our important prescription drug is currently marketed and sold through a syndicate of seven commercial partners in numerous key markets throughout the world with submissions seeking approval under regulatory reviews in numerous other countries. Learn more about our trusted strategic partners below.